News & Events

• Seres Therapeutics to Host Second Quarter 2021 Financial Results and Operational Progress Conference Call and Webcast on August 3, 2021
  Published on 2021-07-29
• Seres Therapeutics to Host Conference Call and Webcast to Discuss Topline Results from Phase 2b Study of SER-287 to Treat Mild-to-Moderate Ulcerative Colitis
  Published on 2021-07-22
• Seres Therapeutics Announces Topline Results for SER-287 Phase 2b Study in Mild-to-Moderate Ulcerative Colitis
  Published on 2021-07-22
• Vedanta Biosciences Completes $68 Million Series D Financing
  Published on 2021-07-21
• Seres Therapeutics, Nestlé Health Science Announce SER-109 Co-Commercialization License Agreement
  Published on 2021-07-01
• Vedanta Biosciences Presents New Data from Phase 1 Study of VE202, Its Rationally-Defined Consortium for the Treatment of Inflammatory Bowel Disease, at the International Human Microbiome Consortium Congress 2021 (IHMC)
  Published on 2021-06-29
• Seres Therapeutics to Present at JMP Securities Life Sciences Conference
  Published on 2021-06-10
• Seres Therapeutics to Host Virtual Investor Event on June 21, 2021
  Published on 2021-06-10
• Seres Therapeutics Presents Research from its Early-Stage Microbiome Therapeutic Oncology Programs at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
  Published on 2021-06-04
• Seres Therapeutics Announces FDA Clearance of IND for SER-155, an Investigational Microbiome Therapeutic for the Prevention of Antibiotic-Resistant Bacterial Infections and Graft-versus-Host Disease (GvHD)
  Published on 2021-06-01
• Seres Therapeutics to Present at Upcoming Virtual Investor Conferences
  Published on 2021-05-25
• Seres Therapeutics Presents Data Across its Broad Microbiome Pipeline Including New 24-Week Data from SER-109 Phase 3 ECOSPOR III Study in Recurrent C. Difficile Infection at Digestive Disease Week 2021
  Published on 2021-05-21
• Seres Therapeutics Announces David Arkowitz to Join as Executive Vice President, Chief Financial Officer and Head of Business Development
  Published on 2021-05-20
• Seres Therapeutics to Present Clinical Research on the Microbiome’s Impact on Allogeneic Hematopoietic Stem Cell Transplantation and Cancer Immunotherapy at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting
  Published on 2021-05-19
• Seres Therapeutics to Present at RBC Capital Markets 2021 Global Healthcare Conference
  Published on 2021-05-12